Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept + LV5FU2 in First-Line Metastatic Colorectal Cancer
NCT02384759Phase 2Completed
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- May 2015
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in colorectal cancer (CRC), sponsored by Fédération Francophone de Cancérologie Digestive. Started May 2015; status: completed.
02
Drugs
aflibercept
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02384759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384759.